Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Oct;29(10):1118-42.
doi: 10.1038/modpathol.2016.92. Epub 2016 Aug 1.

Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine

Ruifang Sun  1   2 , L Jeffrey Medeiros  1 , Ken H Young  1   3
Affiliations
Free article
Review

Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine

Ruifang Sun et al. Mod Pathol. 2016 Oct.
Free article

Abstract

Lymphomas are a group of hematological malignancies derived from lymphocytes. Lymphomas are clinically and biologically heterogeneous and have overlapping diagnostic features. With the advance of new technologies and the application of efficient and feasible detection platforms, an unprecedented number of novel biomarkers have been discovered or are under investigation at the genetic, epigenetic, and protein level as well as the tumor microenvironment. These biomarkers have enabled new clinical and pathological insights into the mechanisms underlying lymphomagenesis and also have facilitated improvements in the diagnostic workup, sub-classification, outcome stratification, and personalized therapy for lymphoma patients. However, integrating these biomarkers into clinical practice effectively and precisely in daily practice is challenging. More in-depth studies are required to further validate these novel biomarkers and to assess other parameters that can affect the reproducibility of these biomarkers such as the selection of detection methods, biological reagents, interpretation of data, and cost efficiency. Despite these challenges, there are many reasons to be optimistic that novel biomarkers will facilitate better algorithms and strategies as we enter a new era of precision medicine to better refine diagnosis, prognostication, and rational treatment design for patients with lymphomas.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Blood. 2011 Jan 20;117(3):915-9 - PubMed
    1. Blood. 1995 Aug 15;86(4):1534-9 - PubMed
    1. Cancer. 2014 Jun 15;120(12):1818-29 - PubMed
    1. Blood. 2004 Jan 1;103(1):275-82 - PubMed
    1. Blood. 2013 Oct 10;122(15):2630-40 - PubMed

Publication types

Substances

LinkOut - more resources